

Aus dem Universitätsinstitut für Klinische  
Chemie (UKC), Inselspital Bern

Direktorin  
**Prof. Dr. med. Martin Fiedler**

Arbeit unter der Leitung von  
**Prof. Dr. Dr. med. Michael Nagler**

***Immunoabsorption for the treatment of  
acquired hemophilia: new observational data,  
systematic review and meta-analysis***

Inaugural-Dissertation zur Erlangung der Doktorwürde  
der Humanmedizin der Medizinischen Fakultät der  
Universität Bern

vorgelegt von  
**Esteves Pereira Michael**  
aus Portugal

akzeptiert zur Publikation in *Transfusion Medicine Reviews*

Von der Medizinischen Fakultät der Universität Bern  
auf Antrag der Dissertationskommission als Dissertation  
genehmigt.

*Promotionsdatum:*

**Der Dekan der Medizinischen Fakultät:**



This work is licensed under a Creative Commons Attribution 4.0 International License.

ORIGINAL ARTICLE

## **Immunoadsorption for the treatment of acquired hemophilia: new observational data, systematic review and meta-analysis**

MICHAEL ESTEVES PEREIRA\*, CHRISTOPH BOCKSRUCKER\*, JOHANNA ANNA KREMER HOVINGA<sup>\*†</sup>, MARTIN MUELLER<sup>§</sup>, MICHAEL DASKALAKIS<sup>\*†</sup>, BEHROUZ MANSOURI TALEGHANI<sup>\*†¶</sup>; AND MICHAEL NAGLER <sup>\*‡¶</sup>

*\* Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland; †Department of Clinical Research, University of Bern, Bern, Switzerland; § Department of Emergency Medicine, Inselspital, Bern University Hospital, Bern, Switzerland; ‡ University Institute of Clinical Chemistry, Inselspital University Hospital, 3010 Bern, Switzerland; ¶ shared last-authorship*

Correspondence: Michael Nagler, MD, PhD, MSc; University Institute of Clinical Chemistry, Inselspital University Hospital, 3010 Bern, Switzerland; michael.nagler@insel.ch; phone +41 31 664 0520; fax +41 31 632 4862

<i>Running head:</i>	IA for acquired hemophilia
<i>Text word count:</i>	4477
<i>Abstract word count:</i>	248
<i>Figures:</i>	5
<i>Tables:</i>	4
<i>References:</i>	64
<i>Keywords:</i>	Factor VIII deficiency, acquired Immunosorbent Techniques Therapeutics Hemorrhage/ drug therapy Hemostatics/ therapeutic use

## ABSTRACT

The treatment of patients with acquired hemophilia is challenging due to life-threatening hemorrhages, delayed response, and adverse effects to immunosuppressive agents. Even though immunoadsorption (IA) rapidly removes autoantibodies against factor VIII, this intervention's effectiveness is still a matter of debate.

We aimed to study important outcomes of IA as adjunctive treatment in patients with acquired hemophilia. We performed comprehensive literature searches in MEDLINE and EMBASE databases. Clinical and laboratory data of all patients treated in our institution were additionally included.

Literature searching yielded 498 records, of which eleven studies describing 116 patients were finally included. The number of patients varied from 1 to 65, and patients' ages ranged between 14 and 89. Treatment criteria in most patients were (a) failed response to immunosuppressive treatment alone, and/or (b) uncontrollable bleeding episodes, and/or (c) high inhibitor titer. Methodological quality was moderate. The number of IA sessions varied from 1 to 24. Within our institution, 12 patients have been treated since 2002; median age was 76 years (range 34, 86); median titer of factor VIII inhibitor was 20 Bethesda units (range 3, 214). Pooled estimates, modeling a random-effect binominal distribution incorporating the Freeman-Tukey double arcsine transformation, were 86% in case of factor VIII recovery (95% confidence interval 76% to 94%), 95% for reduction of factor VIII inhibitor (83%, 100%), and 7% in case of death (0%, 18%).

Our data suggest that IA might be a beneficial adjunctive treatment in patients with high-risk acquired hemophilia, but future studies shall confirm this observation.

## INTRODUCTION

Treatment of patients with acquired hemophilia is challenging. Often, patients present with large ecchymosis, extensive muscle hemorrhages, gastrointestinal bleeding, or even intracerebral hemorrhage [1-3]. The mortality is high because of bleeding complications and treatment complications such as infection [4, 5]. The pathogenesis of acquired hemophilia is heterogeneous. The most common associated conditions are malignancy [6, 7], autoimmune disorder [8-11], drug-induced [12, 13], or post-partum status [14, 15]. On multivariate analysis, factors that predict improved overall survival are the achievement of complete remission, age below 65 years, and postpartum status. The largest patient cohort has been described by the EACH2 registry of 501 patients [16]. The cohort comprised 266 men (53.1%) and 235 women (46.9%). The median age at diagnosis was 73.9 years, demonstrating a preponderance of older patients but the data revealed also a second small population of younger female patients (n= 42; 8.4%) with a median age of 33.9 years who presented with peripartum acquired hemophilia (8 antepartum and 34 postpartum). Whereas the whole EACH2 cohort showed upon treatment a CR of 73% and a preliminary survival rate of 68% at final follow up, 36/42 women were in CR (86%), and 40/40 (100%) alive at final follow up [17]. This excellent survival reflects the younger age and better overall health of the female subgroup and has been described by other retrospective studies and reviews.

Physicians are confronted with a variety of drugs to stop the bleeding and eradicate the inhibitor against factor VIII (FVIII) [5, 18-20]. However, results from randomized controlled trials to inform physicians regarding treatment decisions are not available. Stopping the bleeding is the first treatment objective, which is pursued using recombinant activated factor VII, porcine factor VIII, activated prothrombin complex concentrate, or even high-dose human factor VIII [4, 5, 18, 20, 21]. To prevent additional bleeding, some patients have been treated with emicizumab, a bispecific factor VIIIa mimetic antibody, with interesting responses [22]. Even though it is not yet approved for acquired hemophilia and clinical trials are missing, it has possible hemostatic prophylactic effectivity with weekly or bi-weekly s.c.-application, can be done in an outpatient setting, and is bridging the time until immunosuppression is effective. To eradicate inhibitors against factor VIII, a combined immunosuppressive treatment can be applied. Often, a combination of corticosteroids and cyclophosphamide is given [18, 23]. However, response to treatment might take several weeks or even months and the treatment is not successful in a relevant number of patients [16, 24-26]. Other immunosuppressive regimens include azathioprine, mycophenolate mofetil, and

bortezomib [27, 28]. Because of the low rate of adverse events, Rituximab has recently gained increasing acceptance in combination with steroids, used in the first line or the second line after no response to cyclophosphamide and steroid treatment, but these regimes have not yet been studied in controlled trials [17, 29-31].

IA (IA) is suggested to rapidly eradicate autoantibodies against factor VIII by removing circulating immunoglobulins [32]. Patient plasma is separated from whole blood using a plasma separation device and it is passed through columns containing absorbent ligands [33-35]. Several adsorbent ligands are used: (a) re-usable columns comprised of *Staphylococcus aureus* protein A and bound to sepharose matrix (protein A sepharose) [36-38], (b) re-usable columns with anti-human IgG sheep bound to sepharose matrix (Therasorb®-Ig) [36-38], (c) disposable tryptophan-based columns (Immusorba® TR-350) [39-41], and (d) a synthetic peptide GAM bound to sepharose matrix (Globaffin) [42, 43]. With most columns, IgG immunoglobulins are selectively removed [36] and the inhibitor titers of the autoantibodies are lowered significantly within few sessions [44]. However, publications describing the clinical effectiveness of this approach are scarce and scattered in the literature. Comparable to other rare diseases, no randomized controlled trials have been conducted. Thus, no conclusion or recommendation as to whether or not IA should be implemented in treatment regimens for acquired hemophilia has been made to date [4, 18, 23, 36, 45-47].

## Aim

The aim of the present investigation was to systematically search and retrieve available clinical and laboratory data from studies describing the use of IA for the treatment of acquired hemophilia, to report on patients treated on our own institution in this way, and to summarize all data using meta-analytic methods.

## METHODS

### Study design and setting

In a retrospective cohort study, we systematically searched and retrieved data from all patients with acquired hemophilia treated at our institution between 2002 and May 2019. Inselspital Bern is the only tertiary hospital in the Greater Bern Area covering more than 1.5 million inhabitants. Due to the retrospective design and absence of general informed consent of patients attending the hospital before 2016, not all patients had provided informed consent – the local ethics committee waived this need. The local ethics committee approved the protocol

(Ethikkommission Bern #2019-00478) and we conducted the study in accordance with the Declaration of Helsinki.

### **Inclusion criteria and identification of patients**

Patients were identified from the patient documentation within the apheresis unit. Inclusion criteria were an established diagnosis of acquired hemophilia with a FVIII activity below 5 IU/dl and an inhibitor titer  $>1$  BU/ml. Predefined clinical data including year of diagnosis, age at admission, sex, bleeding presentation, concomitant disorders, aPTT, FVIII activity and inhibitor titer were retrieved in duplicate (MP, MN) from electronic patient documentation. In addition, FVIII recovery, reduction of the inhibitor titer, bleeding events and deaths were recorded at predefined follow-up time points: 30 days, 3 months and 12 months. A specifically designed data extraction form was used, and the accuracy was checked by a second investigator (MN). Discrepancies were resolved by discussion.

### **Systematic review: Study identification, eligibility and data extraction**

A search strategy for MEDLINE and EMBASE was developed using the Ovid interface and refined using keywords from references found in a pilot search and after manual review of reference lists (supplementary material). No restrictions with regard to language or publication date were applied. The last search run was performed on October 29th, 2019 and obtained records were screened by 2 investigators in parallel (M.N., M.P.). The titles and abstracts of all hits were assessed for eligibility. The following inclusion criteria were applied: (1) acquired hemophilia patients with factor VIII levels below 20%, and an inhibitor titer  $\geq 1$ , (2) patients that have had at least one session of IA in addition to standard treatment, (3) laboratory outcomes reported (factor VIII recovery and/or course of inhibitor titer), and (4) reporting of clinical outcomes (bleeding events and/or mortality). Studies were excluded if (a) only patients with hereditary hemophilia were described, (b) plasma exchange was conducted, (c) no clinical outcomes were reported, or (d) no laboratory outcomes were presented. The most complete publication was selected where multiple publications describing the same cohort were found. Full-text articles were assessed by two investigators. Studies selected for inclusion were reviewed in duplicate and the following data were extracted: author, year of publication, number of patients, age range, sex, aPTT, FVIII, inhibitor titer, co-treatment and observation period. The treatment protocols, including the absorbing agent, the number of IA sessions and the co-treatment(s) were extracted, as well as factor VIII-recovery, reduction of the inhibitor titer, remission status and death. The systematic review protocol used here was submitted to the PROSPERO international prospective register of systematic reviews and the results have been reported according to the PRISMA guideline.

### **Assessment of methodological quality**

For assessment of methodological quality, we used the Newcastle-Ottawa Scale (NOS; [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp)). The NOS is an established tool to assess the methodological quality of nonrandomised studies including case-control and cohort studies [48]. The following items were assessed: (a) representative patients, (b) control group selected, (c) patients treated, (d) endpoints absent at the start of treatment, (e) control group comparable, (f) determination of endpoints, (g) interval of follow-up, and (h) complete follow-up.

### **Definition of outcomes**

Factor VIII recovery or complete remission, respectively, was defined as a stable FVIII recovery of higher than 70 IU/dl. Partial remission was defined as a factor VIII recovery of more than 30 IU/dl [49]. Reduction of inhibitor titer was defined as a titer below 10 BU/ml and/or a decline of more than 70% [50]. Mortality was defined as overall mortality or the proportion of patients who died within the given observation period.

### **Statistical analysis**

For descriptive purposes, numbers / proportions and median / range were used as appropriate. Pooled proportions of patients with factor VIII recovery (complete response), reduction of inhibitor titer and deaths were calculated in relevant subgroups using the binominal distribution and Freeman-Tukey double arcsine transformation [51, 52]. Heterogeneity was tested using the  $I^2$  statistics, which describes the proportion of total variation due to between-study heterogeneity. Sensitivity analyses were conducted in retrospective studies and in studies using different absorbing agents (Protein A sepharose vs. Ig-Therasorb vs. Immuno-sorba TR-350). The Stata 14.1 statistics software package (StataCorp. 2015. Stata Statistical Software: Release 14.2. College Station, TX, USA: StataCorp LP) was used for statistical analyses.

## **RESULTS**

### **Characteristics, treatment, and outcomes**

Within our institution, 12 patients with acquired hemophilia have been treated since 2002; detailed patient characteristics are shown in Table 1. The median age was 76 years (range 34, 86) and 4 patients were female. The bleeding phenotype was extensive bruising and/ or muscle hematomas in nine patients, gastrointestinal bleeding in two patients and extensive bleeding after tooth extraction in one patient. At admission, median aPTT was 72.5 seconds (range 52, 130), factor VIII activity was below 1 IU/dl in 9 patients, and median factor VIII inhibitor was 20 BU/ml (range 3, 214). Treatment criteria for IA was either (1) failed response to



immunosuppressive therapy alone, (2) severe bleeding episodes that could not be controlled, or (3) high inhibitor titer. Clinical and laboratory outcomes are reported in Table 2. Observation period varied from 22 days to 4 years and the number of IA sessions varied from 2 to 9. In each session, we treated 2 - 2.5 times the patients' plasma volume. Cyclophosphamide was used in addition to steroids (prednisolone in 10 patients and methylprednisolone in 2 patients) as immunosuppressive treatment in all patients. Other factor concentrates (recombinant factor VIIa, activated prothrombin complex concentrate, (human) factor VIII concentrate), and intravenous immunoglobulin G were used in some patients. At day 30, the median factor VIII was 34 IU/dl (range <0.01, 241) and the median inhibitor titer was 1.1 BU/ml (range 0, 326.5). At 3 months, the median factor VIII was 80 IU/dl (range 32, 360) and the median inhibitor titer was 0.15 BU/ml (range 0, 2). After one-year, median factor VIII was 147 IU/dl (range 132, 162), and the median inhibitor titer was 0 (for only two available patients). Bleeding could be stopped in 9 patients and 3 patients did not respond to the treatment.

#### **Selection of studies and methodological quality**

Our literature search yielded 498 records (Figure 1). After removal of duplicates, the title and abstract were screened in 444 records. We selected 52 publications for full-text review of which 42 were excluded because IA was not applied, because of double publication, or missing data. Adding our own data, we included eleven studies comprising 116 patients (Table 3). The overall quality of primary studies according to the adapted NOS was rated as moderate. The most important limitations were that (a) no control group was available, and (b) data were collected retrospectively in all but one case [53]. Thus, items 2 and 5 from the adapted NOS were rated as “unfavorable” in all studies; the ratings of the other items of NOS are shown in Figure 2. The study populations were regarded as “very representative” because all patients were treated in 3 out of 11 studies, and “somewhat representative” in all other studies. The items “Were patients really treated” and “Were endpoints absent at the time of inclusion” were rated as “Yes” in all studies. For all endpoints, data were available, but no blinded assessment was done. Follow up was carried out  $\geq 3$  months in 9 of the 11 studies, and the frequency of patients lost to follow-up was below 20% in all studies. The individual ratings for all studies are shown in Table 1 of the supplementary material.

#### **Systematic review**

Reports of one-hundred and sixteen patients with acquired hemophilia treated with IA were identified; the observation period varied between 43 days [37] and 14 years [53]. Details are reported in detail below, patient characteristics are summarized in Table 3, treatment details and outcomes are given in Table 4.

In a retrospective analysis, Gjoerstrup and colleagues report about three non-pregnant patients (43, 62, and 75 years of age; one female) with acquired hemophilia [54]. The treatment indication was acute bleeding, and all patients had high inhibitor titers (36, 850, and 1'500 BU/ml). Two to four cycles of IA using Immunosorba® protein A sepharose were applied in addition to steroids, cyclophosphamide, intravenous immunoglobulins, and factor VIII concentrate. Recovery of FVIII and a marked reduction of the inhibitor titer was observed in 2 out of three patients; no deaths occurred. No side effects were reported, and the observation period was not mentioned.

Watt and colleagues summarized data of nine non-pregnant patients with acquired hemophilia (median age 58 years, range 14 to 76; 3 females), which were included in an application of an Investigational Device Exemption (IDE) to the Food and Drug Administration (FDA) [50]. The median FVIII activity was 5 IU/dl (range <5 to 8), and the median inhibitor titer was 600 BU/ml (range 8 to 1587); the treatment indication was severe bleeding. Two to six IA cycles using protein A sepharose were used, and various additional treatments were applied. Even though the inhibitor's titer was markedly reduced in 7/7 patients (not recorded in 2 patients), FVIII recovery was achieved only in 5/7. The bleeding stopped in all but one patient. No deaths were reported, but the observation period was four weeks only. Adverse events were assessed carefully, and grade I events reported: nausea and vomiting in 11% of the procedures, paresthesia due to chelation of ionized Ca<sup>2+</sup> in 10%, and mild hypotension in 6%.

In another retrospective analysis, Jansen and colleagues report about seven patients with acquired hemophilia (median age 58, range 24 to 76; two female), including one patient with a pregnancy-associated disease, and one patient with preexisting rheumatoid disease [55]. The treatment indication was severe bleeding in 4 cases and high inhibitor titer in all other cases (median titer 114 BU/ml, range 18 to 540; median FVIII activity <1 IU/dl, range <1 to 15). In addition to steroids and cyclophosphamide, patients received FVIII, activated factor VII (aFVII), activated prothrombin complex concentrate (aPCC), or fresh frozen plasma (FFP). Four to nineteen cycles of IA using Therasorb®-Ig were applied. Recovery of FVIII and marked reduction of the inhibitor titer was recorded in 6/7 patients. Remission was not achieved in an elderly male patient (76 years) with a high inhibitor titer (540 BU/ml). No deaths were reported over an observation period of several months (not specified); mild side effects, including nausea and flushing, was reported in 6% of the cycles.

Guillet and colleagues retrospectively describes two patients [37]: A 29-year-old male patient with underlying autoimmune disease who experienced massive abdominal hemorrhage with

shock following a liver biopsy (FVIII <0.01 IU/ml, inhibitor titre 80 BU/ml), and a 62-year-old female patient with rheumatoid arthritis and massive retroperitoneal hemorrhage (FVIII = 0.03 IU/ml, inhibitor titre 15 BU/ml). Indication for IA was a treatment-refractory situation in both cases. Three or four IA cycles using protein A sepharose were applied in addition to porcine FVIII, APCC, and steroids (case 1) or steroids, cyclophosphamide, and rFVIIa (case 2), respectively. Even though a marked reduction in the inhibitor titre was observed in both patients, complete FVIII recovery was observed in one patient only (observation period one year). One patient died due to septic shock.

In another retrospective study, Mansouri et al reports about four patients followed for an observation period of 2 to 5 years [56]: a 27-year-old female with pregnancy-associated IA (76 BU/ml), a 63-year-old female (123 BU/ml), a 54-year-old male (138 BU/ml), and a 67-year-old male (3 BU/ml). Treatment indication was severe bleeding and high inhibitor titer (three patients). Further patient characteristics were not given. One to four IA cycles using protein A sepharose were applied in addition to steroids and cyclophosphamide. Recovery of FVIII and reduction of inhibitor titer were observed, no side effects or death occurred.

Rivard and colleagues retrospectively report on one female patient with pregnancy-associated acquired hemophilia (28-year-old), a 67-year-old male patient with concomitant bladder cancer, an 80-year-old female with cardiopulmonary comorbidities, a 59-year-old male, and a 59-year-old female [57]. Treatment indication was high inhibitor titer (median 100 BU/ml, range 12 to 144), persistent bleeding despite treatment, or serious comorbidities (patient 2). FVIII was 1 (<1 to 15) IU/dl. Four to five IA cycles using protein A sepharose were applied in addition to steroids, cyclophosphamide, and various factor concentrates (Table 2). Recovery of FVIII and marked reduction of inhibitor titer was observed in four out of five patients. In the 80-year-old female patient, no remission was achieved, and bleeding was ongoing. The patient died after all treatment was stopped intentionally. A hematoma related to the central line was reported as a side effect; the median observation period was three years.

Brozka and colleagues conducted a retrospective analysis in nine non-pregnant patients followed for a median of two years [39]. The median age was 70 years (range 50 to 78), three patients were female. Various comorbidities were reported (cancer, polyarthritis, pulmonary disease, diabetes, and bullous pemphigoid). The median FVIII activity was 2 IU/dl, median inhibitor titer 37 BU/ml (range 3.61 to 1085). Treatment indication was persistent bleeding, and high inhibitor titer in some cases remained however unclear in other cases. Four to twenty cycles of IA using Immusorba® TR-350 (median 11) were applied in addition to rFVIIa,

steroids, and cyclophosphamide. FVIII recovery was observed in seven patients, and the reduction of the inhibitor titer in 8 patients; two patients died because of persistent bleeding or pneumonia, respectively. No side effects were reported.

The case of a 73-year-old female patient with cerebral bleeding due to acquired hemophilia was reported by Seibert et al [41]. The FVIII activity was 1 IU/dl, inhibitor titer 1'500 BU/ml. Treatment was initiated on day 17 because of persistent bleeding despite steroids, cyclophosphamide, tranexamic acid, rituximab, and mycophenolic acid. After 14 IA cycles using Immusorba® TR-350, bleedings stopped, FVIII increased to 5% and the inhibitor titer was 23 BU/ml. Further follow-up was not conducted.

Zeitler and colleagues prospectively developed a treatment protocol and treated 65 patients with acquired hemophilia, details of which were reported in various publications [49, 53, 58-62]. Most data were retrieved from the most complete article [53], but other publications were also used. The median age was 67 years (28 to 89), 58% of the patients were female.

Pregnancy-associated acquired hemophilia was present in 6 patients, eight patients suffered from autoimmune disorders, and five patients had cancer. Treatment indication was a high inhibitor titer ( $> 5$  BU/ml), the median inhibitor titer was 228 BU/ml (range 8 to 3600), and median FVIII was below 1 IU/dl. The protocol consists of 16 IA cycles using Therasorb®-Ig in addition to prednisolone and cyclophosphamide; azathioprine, vincristine, rituximab was given in some cases. FVIII recovery was observed in 54 cases (83%; partial recovery in five more patients), reduction of the inhibitor titer in 63 patients. Six patients died in an observation period between one and 14 years, the cause of which was assigned to cancer or infection. Serious side effects were not reported.

Bilgin and colleagues reported a 78-year-old male patient with chronic obstructive pulmonary disease who presented with multiple ecchymoses and hematomas [63]. FVIII was  $<1$  IU/dl, and the inhibitor titer was 44 BU/ml. Indication for IA was failed treatment with rFVIIa, steroids, and cyclophosphamide, and ongoing bleeding. FVIII recovery and the reduction of inhibitor titer were achieved after five IA cycles; the columns were not reported. Even though bleeding stopped rapidly, FVIII recovered, and inhibitor titer was 0 BU/ml, the patient died after six months due to pulmonary disease.

### **Meta-analysis**

The pooled proportion of patients with VIII recovery as defined above (complete remission) was 86% (95% confidence interval [CI] 76%, 94%), the  $I^2$  statistics was 0%. The forest plot is shown in Figure 3. The pooled proportion of patients with a reduction of the inhibitor titer

was 95% (95%CI 83%, 100%), the  $I^2$  statistics was 32% (Figure 4). The pooled mortality was 7% (95%CI 0%, 18%;  $I^2=24\%$ ; Figure 5). Sensitivity analyses did not reveal any significant differences in retrospective studies or in studies using different absorbing agents (Protein A sepharose vs. Therasorb®-Ig vs. Immusorba® TR-350).

## Discussion

The number of studies investigating IA for the treatment of acquired hemophilia is limited and most of them are retrospective case series. Additionally, observation period varied between few days and several years. Many patients were treated because of a high inhibitor titer, severe bleeding events, or a failed response to routine treatment with steroids and cyclophosphamide. Recovery of FVIII and reduction of the inhibitor titer was achieved in the majority of patients, while the mortality was limited. Factors associated with study design, patient population, or treatment details affecting clinical outcomes were not apparent.

This is the first systematic review summarizing available literature on IA for the treatment of acquired hemophilia and pooling available data. The results extracted from our analysis are better than in most previous studies conducted without IA. A complete remission frequency of 73% has been reported in the European EACH2 registry [16]. In a study conducted in Germany, Austria, and Switzerland (GTH-AH), a complete remission was observed in 61% of the patients [26]. In a UK-based surveillance study, complete remission occurred in 71% of the patients [25]. In the French SACHA study, complete remission was reported in 61% of the patients [24]. Our results are favorable also with regard to mortality (26% in EACH2, 33% in GTH-AH, 43% in the UK study, and 33% in SACHA). And it is noteworthy that patients treated with IA are at a high-risk for bleeding or in a treatment-refractory situation.

The strength of our investigation is that we conducted a comprehensive literature search using a well-designed search strategy and covering two major databases (MEDLINE, EMBASE). In addition, we applied strict inclusion criteria and two investigators searched the literature and retrieved the data in parallel. Our study has limitations, however, and we cannot fully exclude that this might have influenced our results. First, the methodological quality was moderate only and no control group was included in any study. As with other rare diseases, no randomized controlled trials are available studying the treatment of acquired hemophilia. This makes it impossible to accurately assess the actual ‘added value’ over the rest of the treatment. However, the Factor VIII recovery rate was high despite the patients being treated being at high risk for bleeding and in a treatment-refractory situation. Secondly, we cannot

fully exclude a publication bias resulting from unsuccessful treatments that were not published. However, most authors mention that the patient cohort is complete with regard to all patients treated. Thirdly, pooled estimates of proportions might be imprecise and even biased if studies have either 0 or 1 or in case of extreme differences in the number of participants in case Freeman-Tukey double arcsine transformation is used [64]. However, we believe that the risk is low in our study because (a) the differences in study size are much smaller than in the analysis mentioned above, and (b) the magnitude of the effect sizes is comparable among studies if case reports are excluded. Fourthly, we were not able to conduct a proper sensitivity analysis because primary studies did not provide data on different cut-offs. Even though we cannot fully conclude that this might have introduced any bias, we did not have identified apparent sources of variability. Fifthly, the observation periods varied remarkably, even within studies, and we cannot entirely exclude that this might have introduced any bias. However, there are currently no studies available with a better methodology.

Even though firm evidence is still lacking and the actual ‘added value’ of immunoabsorption cannot be adequately assessed, we believe that IA might be a beneficial adjunctive treatment modality in some patients with acquired hemophilia. It was associated with a complete remission in the majority of patients, most of whom are at high risk of bleeding. Few side effects were reported; most of them were mild only (nausea and vomiting; paresthesia; and mild hypotension). However, a central venous catheter is often used, exposing the patient to a risk of bleeding and infection. Thus, we believe that adjunctive IA is justified in selected high-risk patients with acquired hemophilia. The question arises whether IA might improve clinical outcomes in the long-term. Even though rates of platelet recovery, reduction of inhibitor titre, and death are at least comparable to large registries of unselected patients [16], outcomes cannot be compared directly because of different observation periods. This issue must be clarified in future studies directly comparing different treatment strategies. Although IA is, *per se*, an expensive procedure, the often-necessary regular treatment of this patient group with FVIII bypassing agents is very much higher and may even be already be justified, if this period can be shortened by one or two days. Indeed, some authors have previously argued that the expenditure associated with IA is counterbalanced by a reduced need for coagulation factors such as rFVIIa or pFVIII [34, 55]. IA is only available in a limited number of specialized centers in Switzerland. The procedure takes about 6-8 hours and has to be done in combination with a regular apheresis machine for plasma separation. An IA with a non-reusable column is reimbursed with ca. 1500 CHF per adsorption round. Using an IA with a

reusable column, the reimbursement is ca. 3000 CHF per adsorption round. At our institution, IA is considered on a case-by-case base rather than a strict cut-off level. Strong arguments are (a) live-threatening bleeding complications, (b) inhibitor titers  $\geq 20$  BU/ml, or (c) failed immunosuppressive treatment with corticosteroids and cyclophosphamide using an established dose regimen [3].

In conclusion, our data suggest that IA might be a beneficial adjunctive treatment modality in high-risk patients with acquired hemophilia. Future register data would be expected to add important information to the current state of knowledge.

## Authorship

### *Contribution:*

MN designed the study, collected the data, conducted the analysis, interpreted the results and wrote the manuscript. MEP collected the data, wrote the manuscript and contributed to analysis and interpretation. BMT implemented IA at our institution and contributed to study design and interpretation of results. MM contributed to the analysis plan, analysis and interpretation. CB, JAKH, and MD provided data and contributed to the interpretation of results. All authors contributed to the manuscript.

### *Conflict-of-interest disclosure:*

The authors declare no competing financial interest.

### *ORCID profiles:*

M.N., 0000-0003-4319-2367

### *Correspondence:*

Michael Nagler, MD, PhD, MSc; University Institute of Clinical Chemistry, Inselspital University Hospital, 3010 Bern, Switzerland; michael.nagler@insel.ch; phone +41 31 664 0520; fax +41 31 632 4862

## References

- [1] P. Knobl. Prevention and Management of Bleeding Episodes in Patients with Acquired Hemophilia A, *Drugs* 2018; 78:1861-1872.
- [2] R. Kruse-Jarres, C.L. Kempton, F. Baudo, P.W. Collins, P. Knoebel, C.A. Leissinger, A. Tiede, C.M. Kessler. Acquired hemophilia A: Updated review of evidence and treatment guidance, *Am J Hematol* 2017; 92:695-705.

- [3] A. Tiede, P. Collins, P. Knoebl, J. Teitel, C. Kessler, M. Shima, G. Di Minno, R. d'Oiron, P. Salaj, V. Jimenez-Yuste, A. Huth-Kuhne, P. Giangrande. International recommendations on the diagnosis and treatment of acquired hemophilia A, *Haematologica* 2020; 105:1791-1801.
- [4] P. Giangrande. Acquired hemophilia. Montréal: World Federation of Hemophilia (WFH); 2012, p. 1-7.
- [5] S. Shetty, M. Bhave, K. Ghosh. Acquired hemophilia a: diagnosis, aetiology, clinical spectrum and treatment options, *Autoimmun Rev* 2011; 10:311-316.
- [6] I. Hauser, K. Lechner. Solid tumors and factor VIII antibodies, *Thromb Haemost* 1999; 82:1005-1007.
- [7] S. Sallah, J.Y. Wan. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients, *Cancer* 2001; 91:1067-1074.
- [8] D. Green, K. Lechner. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII, *Thromb Haemost* 1981; 45:200-203.
- [9] D. Green, P.T. Schuette, W.H. Wallace. Factor VIII antibodies in rheumatoid arthritis. Effect of cyclophosphamide, *Arch Intern Med* 1980; 140:1232-1235.
- [10] R.M. Soriano, J.M. Matthews, E. Guerado-Parra. Acquired haemophilia and rheumatoid arthritis, *Br J Rheumatol* 1987; 26:381-383.
- [11] H.S. Ballard, G. Nyamuswa. Life-threatening haemorrhage in a patient with rheumatoid arthritis and a lupus anticoagulant coexisting with acquired autoantibodies against factor VIII, *Br J Rheumatol* 1993; 32:515-517.
- [12] M. Franchini, G. Gandini, T. Di Paolantonio, G. Mariani. Acquired hemophilia A: a concise review, *Am J Hematol* 2005; 80:55-63.
- [13] D.W. Sborov, G.M. Rodgers. Acquired hemophilia a: a current review of autoantibody disease, *Clin Adv Hematol Oncol* 2012; 10:19-27.
- [14] I. Hauser, B. Schneider, K. Lechner. Post-partum factor VIII inhibitors. A review of the literature with special reference to the value of steroid and immunosuppressive treatment, *Thromb Haemost* 1995; 73:1-5.
- [15] J.J. Michiels. Acquired hemophilia A in women postpartum: clinical manifestations, diagnosis, and treatment, *Clin Appl Thromb Hemost* 2000; 6:82-86.
- [16] P. Knoebl, P. Marco, F. Baudo, P. Collins, A. Huth-Kuhne, L. Nemes, F. Pellegrini, L. Tengborn, H. Levesque, E.R. Contributors. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2), *J Thromb Haemost* 2012; 10:622-631.
- [17] L. Tengborn, F. Baudo, A. Huth-Kuhne, P. Knoebl, H. Levesque, P. Marco, F. Pellegrini, L. Nemes, P. Collins, E.r. contributors. Pregnancy-associated acquired haemophilia A: results from the European Acquired Haemophilia (EACH2) registry, *BJOG* 2012; 119:1529-1537.
- [18] F. Baudo, P. Collins, A. Huth-Kuhne, H. Levesque, P. Marco, L. Nemes, F. Pellegrini, L. Tengborn, P. Knoebl, E.r. contributors. Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry, *Blood* 2012; 120:39-46.
- [19] P. Bouvry, P. Recloux. Acquired hemophilia, *Haematologica* 1994; 79:550-556.
- [20] J. Delgado, V. Jimenez-Yuste, F. Hernandez-Navarro, A. Villar. Acquired haemophilia: review and meta-analysis focused on therapy and prognostic factors, *Br J Haematol* 2003; 121:21-35.
- [21] K. Amano, I. Seita, S. Higasa, A. Sawada, M. Kuwahara, M. Shima. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII: analysis of 10-year Japanese postmarketing surveillance data, *Haemophilia* 2017; 23:50-58.
- [22] P. Knoebl, J. Thaler, P. Jilma, P. Quehenberger, K.V. Gleixner, W.R. Sperr. Emicizumab for the treatment of acquired hemophilia A, *Blood* 2020. DOI: 10.1182/blood.2020006315
- [23] D.W. Sborov, G.M. Rodgers. How I manage patients with acquired haemophilia A, *Br J Haematol* 2013; 161:157-165.



- [24] J.Y. Borg, B. Guillet, V. Le Cam-Duchez, J. Goudemand, H. Levesque, S.S. Group. Outcome of acquired haemophilia in France: the prospective SACHA (Surveillance des Auto antiCorps au cours de l'Hemophilie Acquisée) registry, *Haemophilia* 2013; 19:564-570.
- [25] P.W. Collins, S. Hirsch, T.P. Baglin, G. Dolan, J. Hanley, M. Makris, D.M. Keeling, R. Liesner, S.A. Brown, C.R. Hay, U.K.H.C.D. Organisation. Acquired hemophilia A in the United Kingdom: a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation, *Blood* 2007; 109:1870-1877.
- [26] A. Tiede, R. Klamroth, R.E. Scharf, R.U. Trappe, K. Holstein, A. Huth-Kuhne, S. Gottstein, U. Geisen, J. Schenk, U. Scholz, K. Schilling, P. Neumeister, W. Miesbach, D. Manner, R. Greil, C. von Auer, M. Krause, K. Leimkuhler, U. Kalus, J.M. Blumtritt, S. Werwitzke, E. Budde, A. Koch, P. Knobl. Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study, *Blood* 2015; 125:1091-1097.
- [27] A. Tiede, A. Huth-Kuhne, J. Oldenburg, R. Grossmann, U. Geisen, M. Krause, B. Brand, L. Alberio, R. Klamroth, M. Spannagl, P. Knobl. Immunosuppressive treatment for acquired haemophilia: current practice and future directions in Germany, Austria and Switzerland, *Ann Hematol* 2009; 88:365-370.
- [28] F. Baudo, T. Caimi, F. de Cataldo. Diagnosis and treatment of acquired haemophilia, *Haemophilia* 2010; 16:102-106.
- [29] J.C. Boles, N.S. Key, R. Kasthuri, A.D. Ma. Single-center experience with rituximab as first-line immunosuppression for acquired hemophilia, *J Thromb Haemost* 2011; 9:1429-1431.
- [30] M. Franchini, P.M. Mannucci. Inhibitor eradication with rituximab in haemophilia: where do we stand?, *Br J Haematol* 2014; 165:600-608.
- [31] Y. Zeng, R. Zhou, X. Duan, D. Long, S. Yang. Interventions for treating acute bleeding episodes in people with acquired hemophilia A, *Cochrane Database Syst Rev* 2014:CD010761.
- [32] M. von Depka Prondzinski. [Acquired haemophilia due to autoantibodies against factor VIII], *Hamostaseologie* 2003; 23:28-35.
- [33] J. Freedman, M.B. Garvey. Immunoabsorption of factor VIII inhibitors, *Curr Opin Hematol* 2004; 11:327-333.
- [34] J. Freedman, M.L. Rand, O. Russell, C. Davis, P.L. Cheatley, V. Blanchette, M.B. Garvey. Immunoabsorption may provide a cost-effective approach to management of patients with inhibitors to FVIII, *Transfusion* 2003; 43:1508-1513.
- [35] P. Knobl, K. Derfler. Extracorporeal immunoabsorption for the treatment of haemophilic patients with inhibitors to factor VIII or IX, *Vox Sang* 1999; 77 Suppl 1:57-64.
- [36] M. Franchini, M. Sassi, P. Dell'Anna, F. Manzato, G.L. Salvagno, M. Montagnana, M. Zaffanello, G. Targher, G. Lippi. Extracorporeal immunoabsorption for the treatment of coagulation inhibitors, *Semin Thromb Hemost* 2009; 35:76-80.
- [37] B. Guillet, F. Kriaa, M.G. Huysse, V. Proulle, C. George, G. Tchernia, R. D'Oiron, Y. Laurian, B. Charpentier, T. Lambert, M. Dreyfus. Protein A sepharose immunoabsorption: immunological and haemostatic effects in two cases of acquired haemophilia, *Br J Haematol* 2001; 114:837-844.
- [38] I.M. Nilsson, S. Jonsson, S.B. Sundqvist, A. Ahlberg, S.E. Bergentz. A procedure for removing high titer antibodies by extracorporeal protein-A-sepharose adsorption in hemophilia: substitution therapy and surgery in a patient with hemophilia B and antibodies, *Blood* 1981; 58:38-44.
- [39] M. Brzoska, M. Krause, H. Geiger, C. Betz. Immunoabsorption with single-use columns for the management of bleeding in acquired hemophilia A: a series of nine cases, *J Clin Apher* 2007; 22:233-240.

- [40] J. Koessler, A. Kobsar, S. Kuhn, A. Koessler, P. Yilmaz, E. Weinig, E. Putz, M. Boeck, E. Klinker. The effect of immunoadsorption with the Immusorba TR-350 column on coagulation compared to plasma exchange, *Vox Sang* 2015; 108:46-51.
- [41] F.S. Seibert, W. Zidek, T.H. Westhoff. Refractory acquired hemophilia: successful treatment by immunoadsorption with single-use columns, *Ther Apher Dial* 2011; 15:336-337.
- [42] R. Eming, J. Rech, S. Barth, J.R. Kalden, G. Schuler, T. Harrer, M. Hertl. Prolonged clinical remission of patients with severe pemphigus upon rapid removal of desmoglein-reactive autoantibodies by immunoadsorption, *Dermatology* 2006; 212:177-187.
- [43] P. Hamilton, D. Kanigicherla, P. Hanumapura, L. Walz, D. Kramer, M. Fischer, P. Brechley, S. Mitra. Peptide GAM immunoadsorption therapy in primary membranous nephropathy (PRISM): Phase II trial investigating the safety and feasibility of peptide GAM immunoadsorption in anti-PLA2 R positive primary membranous nephropathy, *J Clin Apher* 2018; 33:283-290.
- [44] C. Freiburghaus, E. Berntorp, M. Ekman, M. Gunnarsson, B.M. Kjellberg, I.M. Nilsson. Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995, *Haemophilia* 1998; 4:16-20.
- [45] P.W. Collins. Therapeutic challenges in acquired factor VIII deficiency, *Hematology Am Soc Hematol Educ Program* 2012; 2012:369-374.
- [46] M. Franchini, P.M. Mannucci. Acquired haemophilia A: a 2013 update, *Thromb Haemost* 2013; 110:1114-1120.
- [47] A. Huth-Kuhne, F. Baudo, P. Collins, J. Ingerslev, C.M. Kessler, H. Levesque, M.E. Castellano, M. Shima, J. St-Louis. International recommendations on the diagnosis and treatment of patients with acquired hemophilia A, *Haematologica* 2009; 94:566-575.
- [48] A. Stang. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses, *Eur J Epidemiol* 2010; 25:603-605.
- [49] H. Zeitler, G. Ulrich-Merzenich, D. Panek, G. Goldmann, N. Vidovic, H.H. Brackmann, J. Oldenburg. Extracorporeal Treatment for the Acute und Long-Term Outcome of Patients with Life-Threatening Acquired Hemophilia, *Transfus Med Hemother* 2012; 39:264-270.
- [50] R.M. Watt, K. Bunitsky, E.B. Faulkner, C.M. Hart, J. Horan, J.M. Ramstack, J.L. Viola, J.R. Yordy. Treatment of congenital and acquired hemophilia patients by extracorporeal removal of antibodies to coagulation factors: a review of US clinical studies 1987-1990. Hemophilia Study Group, *Transfus Sci* 1992; 13:233-253.
- [51] M.F. Freeman, J.W. Tukey. Transformations Related to the Angular and the Square Root, *The Annals of Mathematical Statistics* 1950; 21:607-611.
- [52] V.N. Nyaga, M. Arbyn, M. Aerts. Metaprop: a Stata command to perform meta-analysis of binomial data, *Arch Public Health* 2014; 72:39.
- [53] H. Zeitler, G. Goldmann, N. Marquardt, G. Ulrich-Merzenich. Long term outcome of patients with acquired haemophilia--a monocentre interim analysis of 82 patients, *Atheroscler Suppl* 2013; 14:223-228.
- [54] P. Gyorstrup, E. Berntorp, L. Larsson, I.M. Nilsson. Kinetic aspects of the removal of IgG and inhibitors in hemophiliacs using protein A immunoadsorption, *Vox Sang* 1991; 61:244-250.
- [55] M. Jansen, S. Schmaldienst, S. Banyai, P. Quehenberger, I. Pabinger, K. Derfler, W.H. Horl, P. Knobl. Treatment of coagulation inhibitors with extracorporeal immunoadsorption (Ig-Therasorb), *Br J Haematol* 2001; 112:91-97.
- [56] B. Mansouri Taleghani, R. Grossmann. Treatment of patients with factor VIII autoantibodies by staphylococcal protein A-based immunoadsorption and immunosuppression, *Br J Haematol* 2001; 114:956-958.
- [57] G.E. Rivard, J. St Louis, S. Lacroix, M. Champagne, G. Rock. Immunoadsorption for coagulation factor inhibitors: a retrospective critical appraisal of 10 consecutive cases from a single institution, *Haemophilia* 2003; 9:711-716.

- [58] H. Zeitler, G. Ulrich-Merzenich, G. Goldmann, N. Vidovic, H.H. Brackmann, J. Oldenburg. The relevance of the bleeding severity in the treatment of acquired haemophilia - an update of a single-centre experience with 67 patients, *Haemophilia* 2010; 16:95-101.
- [59] H. Zeitler, G. Ulrich-Merzenich, L. Hess, E. Konsek, C. Unkrig, P. Walger, H. Vetter, H.H. Brackmann. Treatment of acquired hemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept, *Blood* 2005; 105:2287-2293.
- [60] H. Zeitler, G. Ulrich-Merzenich, N. Marquardt, J. Oldenburg, G. Goldmann. Immunoabsorption for pregnancy-associated severe acquired hemophilia, *Ther Apher Dial* 2014; 18:103-110.
- [61] H. Zeitler, G. Ulrich-Merzenich, D. Panek, G. Goldmann, N. Vidovic, H.H. Brackmann, J. Oldenburg. Immunoabsorption in the treatment of acquired haemophilia, *Atheroscler Suppl* 2009; 10:122-125.
- [62] H. Zeitler, G. Ulrich-Merzenich, P. Walger, R. Dusing, H. Vetter, H.H. Brackmann. [The modified Bonn Malmo protocol (MBMP) in the treatment of acquired haemophilia A], *Dtsch Med Wochenschr* 2006; 131:141-147.
- [63] A. Ugur Bilgin, M. Ozcan, E. Ayyildiz, O. Ilhan. The treatment of acquired hemophilia with combination therapy of immunosuppressives and immunoabsorption, *Turk J Haematol* 2014; 31:194-196.
- [64] G. Schwarzer, H. Chemaitelly, L.J. Abu-Raddad, G. Rucker. Seriously misleading results using inverse of Freeman-Tukey double arcsine transformation in meta-analysis of single proportions, *Res Synth Methods* 2019; 10:476-483.

## TABLES

**Table 1: Characteristics of patients receiving an IA treatment for acquired hemophilia at our institution, Inselspital, Bern University Hospital**

Patient number	Year of diagnosis	Age	Sex	Type of bleeding	Concomitant disorders	aPTT	FVIII activity	Inhibitor titer
		<i>Years</i>				<i>Seconds</i>	<i>IU/dl</i>	<i>BU/ml</i>
1	2002	77	Female	GI bleeding	Osteoporosis, COPD	52	<1	3
2	2002	75	Female	GI bleeding	Sjogren syndrome	55	<1	18
3	2003	53	Male	Extensive bruising	Chronic hepatitis C	57	<1	16
4	2004	34	Female	Extensive bruising	nr	130	3	>200
5	2006	80	Male	Extensive bruising	CHD, hypertension, renal impairment	65	<1	13
6	2010	70	Female	Extensive bruising, GI bleeding	Sepsis, diabetes type 2	68	3.5	15
7	2012	77	Male	Bleeding after tooth extraction	Granulomatosis with polyangiitis, atrial fibrillation, renal impairment	108	<1	32
8	2013	81	Male	Extensive bruising	Renal impairment, diabetes type 2, CHD	60	2	22
9	2013	64	Male	Extensive bruising	Chronic venous insufficiency	77	<1	214
10	2016	86	Male	Extensive bruising	CHD, renal impairment	84	<1	47
11	2018	73	Male	Extensive bruising	CHD, COPD, renal impairment	119	<1	7
12	2019	77	Male	Extensive bruising, GI bleeding, compartment syndrome	Multiple myeloma, hypertension, atrial fibrillation, renal impairment	119	<1	102

Abbreviations: GI, gastrointestinal tract; COPD, chronic obstructive pulmonary disease; CHD, coronary heart disease

**Table 2: Treatment details and outcomes of patients treated at our institution, Inselspital, Bern University Hospital**

Patient number	Observation period	IA-sessions*	Absorbing agent	Co-treatment	FVIII recovery <sup>#</sup>	Reduction of inhibitor titer <sup>o</sup>	Clinical outcome
	<i>Months</i>				<i>IU/dl</i>	<i>BU/ml</i>	
1	1	2	Protein-A-sepharose	- Cyclophosphamide 75mg/d - IVIG 0.5g/kg/d - rFVIIa 6mg - Prednisolone 75mg/d	34 (30d)	nr	Bleeding stopped
2	1	4	Protein-A-sepharose	- Cyclophosphamide 50mg/d - Prednisolone 100mg/d - IVIG 0.5g/kg/d	2 (30d)	17.6 (30d)	Non-response
3	3	5	Protein-A-sepharose	- IVIG 0.5g/kg/d - FVIII concentrate - Prednisolone 50mg - Cyclophosphamide 100mg/d	34 (30d) 360 (3m)	nr	Bleeding stopped
4	3	6	Protein-A-sepharose	- Prednisolone 75mg/d - Cyclophosphamide - rFVIIa 4.8mg	25 (30d) 62 (3m)	0 (3m)	Bleeding stopped
5	1	3	Protein-A-sepharose	- Cyclophosphamide 100mg/d - Methylprednisolone 125mg/d - Tranexamic acid 500mg 3x/d	241 (30d)	0 (30d)	Bleeding stopped
6	0.8	5	Protein-A-sepharose	- Prednisolone 80mg/d - rFVIIa 90µg/kg - Cyclophosphamide 100mg/d	No recovery	No reduction	No response
7	2	7	Protein-A-sepharose	- Cyclophosphamide 100mg/d - IVIG 0.5g/kg/d  - rFVIIa 90µg/kg - Prednisolone 75mg/d	326.5 (30d)	<1 (30d)	No response; death
8	12	6	Protein-A-sepharose	- Prednisolone 75mg/d - Cyclophosphamide 100mg/d - rFVIIa 90µg/kg	11 (30d) 80 (3m) 132 (12m)	2.1 (30d) 0.3 (3m) 0 (12m)	Bleeding stopped <sup>§</sup>
9	48	4	Protein-A-sepharose	- Cyclophosphamide 100mg/d - IVIG 0.5g/kg/d	194 (30d) 43 (3m) 162(12m)	0.2 (30d) 0.5 (3m) 0 (12m)	Bleeding stopped
10	6	5	Protein-A-sepharose	- Prednisolone 100mg/d - Cyclophosphamide 100mg/d - rFVIIa 90µg/kg	123 (30d) 32 (3m)	1.2 (30d) 2 (3m)	Bleeding stopped; relapse 3 months after diagnosis;

							death 6 months after diagnosis
11	3	9	Protein-A-sepharose	- Methylprednisolone 125mg - aPCC 3700U - rFVIIa 90µg/kg - Cyclophosphamide 100mg/d - Prednisolone 75mg/d	141 (30d) 150 (3m)	0 (30d) 0 (3m)	Bleeding stopped
12	5	7	Globaffin	- Prednisolone 1mg/kg/d - Cyclophosphamide 150mg/d	48 (30d) 199 (3m)	1 (30d) 0 (3m)	Bleeding stopped

\*, Number of IA sessions; #, the factor VIII activity is given at 30 days (30d), 3 months (3m), and 12 months (12m) as available. °, the inhibitor titer in Bethesda units is given at 30 days (30d), 3 months (3m), and 12 months (12m) as available; \$, death 1 year after diagnosis independent from acquired hemophilia

Abbreviations: aFVII, activated factor VII; aPCC, activated prothrombin complex concentrate; IVIG, intravenous immunoglobulin G; nr, not reported

**Table 3: IA treatment of acquired hemophilia: Patient characteristics in primary studies.** Cohort studies, case series and case reports were included.

#	Author, year	No. of patients	Design	Age	Sex	Observation period	aPTT	FVIII activity°	Inhibitor titer°
				<i>Years; median (range)</i>	<i>Numbers male/ female</i>	<i>Years; median or range</i>	<i>Seconds; median (range)</i>	<i>IU/dl; median (range)</i>	<i>BU/ml; median (range)</i>
[54]	Gjörstrup, 1991	3	Retrospective	62 (43 to 75)	2/ 1	nr	nr	nr	63 (36 to 155)
[50]	Watt, 1992	9	Retrospective	58 (24 to 76)	6/ 3	3	nr	5 (<5 to 8)	600 (8 to 1587)
[55]	Jansen, 2001	7	Retrospective	70 (24 to 77)	5/ 2	2.1	90 (70 to 200)	<1 (<1 to 15)	114 (18 to 540)
[37]	Guillet, 2001	2	Retrospective	29/ 62	1/ 1	0.1 to 1	95 to 56	4 (<1 to 7)	15 (22 to 8)
[56]	Mansouri Taleghani, 2001	4	Retrospective	59 (27 to 67)	2/ 2	0.7 (0.25 to 1)	nr	nr	100 (3 to 138)
[57]	Rivard, 2003	5	Retrospective	59 (28 to 80)	2/ 3	3	114 (150 to 122)	1 (<1 to 15)	100 (12 to 144)
[39]	Brzoska, 2007	9	Retrospective	70 (50 to 78)	6/ 3	2	nr	2	37 (3.61 to 1085)
[41]	Seibert, 2011	1	Retrospective	73	0/ 1	nr	89	1	1500
[53]	Zeitler, 2013	65	Prospective	67 (28 to 89)	27/ 38	1 to 14	67 (28 to 89)	<1	228 (8 to 3600)
[63]	Bilgin, 2013	1	Retrospective	78	1/ 0	0.5	157	4	10
Current	Esteves Pereira, 2021	12	Retrospective	76 (range 34, 86)	8/ 4	0.4 (0.1 to 4)	73 (52, 130)	<1 (<1 to 3)	20 (3 to 214)

°, before treatment; nr, not reported

**Table 4: IA treatment of acquired hemophilia: Treatment details and results**

#	Author, year	Nr. of IA*	Absorbing agent	Co-treatment	FVIII recovery	Reduction of inhibitor titer	Death
		<i>median (range)</i>			<i>Number of patients out of all patients</i>	<i>Number of patients out of all patients</i>	<i>Number of patients out of all patients</i>
[54]	Gjörstrup, 1991	2 (2 to 4)	Protein A sepharose	FVIII-concentrates, steroids, cyclophosphamide	2/3	2/3	0/3
[50]	Watt, 1992	3,5 (2 to 6)	Protein A sepharose	Various drugs	5/7	7/7	0/9
[55]	Jansen, 2001	7 (4 to 19)	Therasorb®-Ig	aPCC, steroids, cyclophosphamide	6/7	6/7	0/7
[37]	Guillet, 2001	3.5 (3 to 4)	Protein A sepharose	rFVIIa, steroids, cyclophosphamide	1/2	2/2	1/2
[56]	Mansouri Taleghani, 2001	3 (1 to 4)	Protein A sepharose	nr	4/4	4/4	0/4
[57]	Rivard, 2003	5 (4 to 5)	Protein A sepharose	hFVIII, hFIX, hFXIII, rFVIIa, pFVIII, steroids, cyclophosphamide	4/5	4/5	1/5
[39]	Brzoska, 2007	11 (4 to 20)	Immusorba® TR-350	rFVIIa, steroids, cyclophosphamide	7/9	8/9	2/9
[41]	Seibert, 2011	24	Immusorba® TR-350	Fresh frozen plasma, IVIG, rFVIIa, tranexamic acid, steroids, cyclophosphamide	0/1	0/1	nr
[53]	Zeitler, 2013	16	Therasorb®-Ig	Steroids, cyclophosphamide, azathioprine, vincristine, rituximab	54/65	63/65	6/65
[63]	Bilgin, 2013	5	nr	rFVIIa, steroids, cyclophosphamide	1/1	1/1	1/1
Current	Esteves Pereira, 2021	5 (2 to 7)	Protein A sepharose	Steroids, cyclophosphamide, hFVIII, rFVIIa, tranexamic acid, IVIG, rituximab	8/10	6/8	2/8



**Figure 1: Selection process of primary studies**

**Figure 2: Methodological quality of observational studies according to an adapted Newcastle-Ottawa Scale.** The proportions of studies are shown; the individual items are (1) Are reported patients representative for all treated patients?, (2) Selection of the control group, (3) Were patients really treated?, (4) Were endpoints absent at the time of inclusion?, (5) Are exposed and unexposed patients comparable?, (6) Determination of endpoints, (7) Follow-up time long enough?, (8) Complete follow-up

**Figure 3: Factor VIII recovery in patients with acquired hemophilia treated with IA (complete remission).** The proportions of patients are shown (denoted as estimate, ES). A pooled estimate was calculated using a random-effects binominal distribution incorporating the Freeman-Tukey double arcsine transformation; 95% confidence intervals were computed using the score statistic.

**Figure 4: Reduction of inhibitor titer in patients with acquired hemophilia treated with IA.** The proportions patients are shown (denoted as estimate, ES). Pooled estimate was calculated using a random-effects binominal distribution incorporating the Freeman-Tukey double arcsine transformation; 95% confidence intervals were computed using the score statistic.

**Figure 5: Mortality of patients with acquired hemophilia treated with IA.** The proportions of patients are shown (denoted as estimate, ES). A pooled estimate was calculated using a random-effects binominal distribution incorporating the Freeman-Tukey double arcsine transformation; 95% confidence intervals were computed using the score statistic.

## ***Esteves Pereira et al. supplementary material***

### ***Search Strategy***

Search strategy for EMBASE and Medline via Ovid:

1. exp Hemophilia A/dt, th [Drug Therapy, Therapy]
2. exp Blood Component Removal/ or exp Immunosorbent Techniques/
3. acquired.m\_titl.
4. acquired hemophilia.m\_titl.
5. acquired haemophilia.m\_titl.
6. acquired factor VIII inhibitors.m\_titl.
7. acquired inhibitors.m\_titl.
8. exp Therapeutics/
9. treatment.m\_titl.
10. Coagulation inhibitors.m\_titl.
11. 1 and 2 and 3
12. 4 or 5 or 6 or 7 or 10
13. 8 or 9
14. 12 and 13
15. 11 or 14

*Supplementary Table 1: Ratings of the Newcastle Ottawa Scale*

Author	Year	Are reported patients representative for all treated patients?	Selection of the control group	Were patients really treated?	Were endpoints absent at the time of inclusion?	Are exposed and unexposed patients comparable?	Determination of endpoints	Follow-up long enough?	Complete follow-up
Gjörstrup	1991	Somewhat representative	N/A	Yes	Yes, data presented	N/A	Records available	No	All patients
Watt	1992	Very representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	All patients
Jansen	2001	Somewhat representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	All patients
Guillet	2001	Somewhat representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	lost to follow-up $< 20\%$
Mansouri Taleghani	2001	Somewhat representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	All patients
Rivard	2003	Somewhat representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	lost to follow-up $< 20\%$
Brzoska	2007	Somewhat representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	lost to follow-up $< 20\%$
Seibert	2001	Somewhat representative	N/A	Yes	Yes, data presented	N/A	Records available	No	All patients
Zeitler	2012/2013	Very representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	lost to follow-up $< 20\%$
Bilgin	2013	Somewhat representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	lost to follow-up $< 20\%$
Esteves Pereira	2020	Very representative	N/A	Yes	Yes, data presented	N/A	Records available	Yes ( $\geq 3$ months)	lost to follow-up $< 20\%$